Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority randomized trial

Arase, Yoshitaka; Okubo, Tomomi; Arai, Taeang; Abe, Masanori; Namisaki, Tadashi; Uojima, Haruki; Matsumoto, Kosuke; Kakisaka, Keisuke; Setsu, Toru; Mishima, Yusuke; Tsuruya, Kota; Hirose, Shunji; Deguchi, Ryuzo; Shiraishi, Koichi; Atsukawa, Masanori; Ikegami, Tadashi; Honda, Akira; Terai, Shuji; Yoshiji, Hitoshi; Komori, Atsumasa; Tanaka, Atsushi; Kagawa, Tatehiro

doi:10.1097/hc9.0000000000000827

Public

Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority randomized trial

Published in Hepatology Communications • Oct 7, 2025

Authors:

Yoshitaka Arase

Tomomi Okubo

Taeang Arai

Abstract

BACKGROUND: Osteoporosis is a common complication in patients with primary biliary cholangitis (PBC). This study aimed to compare the efficacy and safety of denosumab and zoledronic acid (ZOL) in treating osteoporosis in PBC patients. METHODS: This multicenter, randomized, open-label trial enrolled ...

Subject

Medicine

Zoledronic acid

Denosumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!